CN111574585B - Cod skin oligopeptide and separation and purification method and application thereof - Google Patents
Cod skin oligopeptide and separation and purification method and application thereof Download PDFInfo
- Publication number
- CN111574585B CN111574585B CN202010455884.5A CN202010455884A CN111574585B CN 111574585 B CN111574585 B CN 111574585B CN 202010455884 A CN202010455884 A CN 202010455884A CN 111574585 B CN111574585 B CN 111574585B
- Authority
- CN
- China
- Prior art keywords
- sephadex
- separation
- skin
- cod
- cod skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a cod skin oligopeptide, a separation and purification method and application thereof. The separation and purification method comprises the following steps: taking Alaska pollack skin as a raw material, and preparing the cod skin collagen peptide mixed peptide by a protease enzymolysis method; sequentially carrying out ultrafiltration treatment, crude separation by a sephadex chromatographic column and high performance liquid chromatography separation; the Sephadex chromatographic column is formed by serially connecting Sephadex G-25 and Sephadex G-50. Activity tests show that the codfish skin oligopeptide has alpha-glucosidase inhibition activity, can assist in reducing blood sugar, and can be used for preparing anti-type II diabetes drugs.
Description
The application is a divisional application with the application number of 201910091803.5 and the application date of 2019-01-30, and the invention is named as 'codfish skin oligopeptide, a separation and purification method thereof and application in preparation of alpha-glucosidase inhibitor and anti-II type diabetes drugs'.
Technical Field
The invention relates to the field of separation and purification and application of fish skin oligopeptides, in particular to Alaska pollock fish skin oligopeptide, a separation and purification method thereof and application of the Alaska pollock fish skin oligopeptide in preparation of alpha-glucosidase inhibitors and anti-II diabetes drugs.
Background
Alaska Pollock. The fish is named as Theragra chalcogramma, lives in the northern part of Atlantic ocean, is a cold water deep sea fish, has tender meat quality and light meat flavor, and due to the special long-term growth environment (low temperature and high pressure), the amino acid composition and the amino acid sequence of fish protein (fish meat, fish skin and the like) of the fish are possibly different from other shallow sea fish, freshwater fish and the like.
The cod skin collagen peptide is a mixture of protein, polypeptide, oligopeptide and amino acid (the content is mainly oligopeptide) prepared by an enzyme method by taking cod skin as a raw material. Wherein the oligopeptide is a small peptide with 2-12 amino acid residues.
For example, chinese patent publication No. CN 108530530 a discloses a method for preparing cod skin collagen peptide, which comprises: 1) removing impurities from fish skin, cleaning, crushing into slurry, and washing with acid, alkali and water to neutrality; 2) adding the fish skin treated in the step 1) into hot water for heat preservation; 3) adding protease into the protein extracting solution obtained in the step 2), and performing enzymolysis treatment twice; 4) removing solid residues from the slurry after enzymolysis by using a centrifugal machine, removing a small amount of macromolecular impurities from the obtained clear liquid by using an ultrafiltration membrane, removing inorganic salts and micromolecular impurities by using a nanofiltration membrane, concentrating to obtain a fish skin collagen peptide solution, and performing spray drying to obtain fish skin collagen peptide powder.
Further, as disclosed in chinese patent publication No. CN 104152518A, a method for preparing cod skin collagen peptide as a food supplement for liver diseases comprises: (1) pretreating cod skin; (2) and (3) carrying out enzymolysis reaction: adding trypsin for enzymolysis reaction; (3) performing ultrafiltration to obtain GM2 component; (4) separating by DEAE-Sepharose FF ion exchange chromatography to obtain GM2-2 component, and freeze drying to obtain collagenase.
However, the collagen peptide or the collagen protease obtained by the technical scheme belongs to macromolecular peptide or protein, and the separation method is not suitable for separation and purification of the cod skin oligopeptide.
The cod skin oligopeptides with small molecular weight are relatively close in molecular weight, and the differences of other physical properties such as electrification property, hydrophobicity and the like are not obvious, so that components with high biological activity cannot be separated by utilizing a traditional membrane separation mode or a chromatographic separation method adopting a single filler.
The biological activities of the presently reported fish skin oligopeptides include antioxidation, blood sugar reduction, immunity improvement, etc., such as WANG (WANG T Y, HSIEH C H, HUNG CC, et al. Fish skin collagen hydrolases as dipeptidyl peptides IV inhibitors and glucose-like peptides-1 peptides precursors, a complex beta peptide in diabetics: a dipeptidyl-peptide J.) hydrolysis of flatfish and tilapia skin, and separation and purification of the hydrolysate can obtain a dipeptidyl peptidase which can promote the secretion of glucagon-like peptide and insulin, and further play a role in regulating blood sugar.
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia, which is caused by defects in insulin secretion or impaired biological action, or both. Hypoglycemic agents are roughly divided into three types according to the hypoglycemic mechanism: (1) stimulating insulin secretion or insulin preparations, such as sulfonylureas; (2) increase the utilization of glucose by peripheral tissues, such as biguanide hypoglycemic agents; (3) alpha-glucosidase inhibitors such as acarbose which is commonly used clinically.
The presently disclosed fish skin oligopeptides with blood sugar reducing effect all play a role in regulating blood sugar according to a mechanism (1), and other blood sugar reducing mechanisms are not disclosed.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides three cod-skin oligopeptides with novel amino acid sequences and a separation and purification process thereof, and activity tests show that the three cod-skin oligopeptides have alpha-glucosidase inhibition activity, can assist in reducing blood sugar and can be used for preparing anti-type II diabetes drugs.
The specific technical scheme is as follows:
the amino acid sequence of the cod skin oligopeptide is Glu-Gly-Gly-Tyr-Thr-Arg, Tyr-Val-Arg or Phe-Tyr-Glu respectively.
The invention also discloses a separation and purification method of the cod skin oligopeptide, which comprises the following steps:
(1) taking Alaska pollack skin as a raw material, and preparing the cod skin collagen peptide mixed peptide by a protease enzymolysis method;
the protease enzymolysis method specifically comprises the following steps:
mixing Alaska pollack skin, pancreatin and water, and carrying out enzymolysis for 6-10 h at the temperature of 52-58 ℃ and under the pH value of 5.5-6.5;
the adding amount of the pancreatin is 0.15-0.25 wt% based on the mass of Alaska pollack skin;
the mass ratio of Alaska pollack skin to water is 1: 4-8;
(2) carrying out ultrafiltration treatment on the cod skin collagen peptide mixed peptide prepared in the step (1) by adopting an ultrafiltration membrane with the molecular weight cutoff of 3000Da, and then concentrating and drying to obtain cod skin collagen peptide;
(3) roughly separating the cod skin collagen peptide prepared in the step (2) by using water as a mobile phase and adopting a sephadex chromatographic column;
the filler of the Sephadex chromatographic column is formed by connecting Sephadex G-25 and Sephadex G-50 in series;
(4) and (4) further separating the crude products obtained in the step (3) by utilizing a high performance liquid chromatography technology to obtain three kinds of cod skin oligopeptides.
Preferably, in step (1), the protease enzymolysis method:
mixing Alaska pollack skin, pancreatin and water, performing enzymolysis at 55 deg.C and pH 6.0 for 8 hr, and heating to 90 deg.C for enzyme deactivation;
the adding amount of the pancreatin is 0.20 wt% based on the mass of Alaska pollack skin;
the mass ratio of Alaska pollack skin to water is 1: 6.
by adopting the optimized enzymolysis process, the yield of the codfish skin collagen peptide mixed peptide obtained after enzymolysis is higher and can reach 75.0%, and activity tests show that the codfish skin collagen peptide mixed peptide has alpha-glucosidase inhibition activity IC50It was 50.4 mg/mL.
Tests prove that in the cod skin collagen peptide mixed peptide obtained by the enzymolysis process:
88.08% of substances with molecular mass of 180-1000 Da and 7.37% of substances with molecular mass of less than 180 Da.
The contents of macromolecular protein, peptide and free amino acid are respectively 0.53g/100mL, 5.20g/100mL and 0.38g/100mL, and the mass ratio of the macromolecular protein, the peptide and the free amino acid is 9: 85: 6.
therefore, the obtained cod skin collagen peptide mixed peptide is mainly oligopeptide with 2-8 amino acid residues.
Preferably, in step (2), the ultrafiltration membrane is selected from a hollow fiber polysulfone ultrafiltration membrane.
In the step (3), the separation is carried out by adopting a mode of serially connecting the Sephadex resins, the specification of a chromatographic column is 2.6 multiplied by 50cm, wherein the Sephadex resin Sephadex G-25(20cm) is filled in the upper layer, the Sephadex resin Sephadex G-50(15cm) is filled in the lower layer, and the middle layer is isolated by quantitative filter paper.
Experiments show that in the separation and purification process, the selection of a Sephadex chromatographic column is particularly critical, and the cod skin collagen peptide with the molecular weight of less than 3000Da after ultrafiltration can be effectively separated only by selecting a mode of serially connecting Sephadex G-25 and Sephadex G-50.
Effective separation of cod skin collagen peptides cannot be achieved when a single Sephadex column, such as Sephadex G-25 or Sephadex G-50 as used in the present invention, or other types of Sephadex columns, such as Sephadex G-10 and Sephadex G-15, are used.
Preferably, in the step (3), Sephadex G-25 is selected from 100 meshes, and Sephadex G-50 is selected from 60 meshes.
Further experiments show that the thickness degree of the gel resin also has influence on experimental results, and when 60-mesh Sephadex G-25 and 60-mesh Sephadex G-50 are used in series, effective separation cannot be realized.
Preferably, in the step (3), the flow rate of the mobile phase is 0.8-1.4 mL/min, and more preferably 1.2 mL/min.
After the crude separation by sephadex chromatography, two separated components are obtained by separation according to the elution sequence and are marked as a separated component A and a separated component B.
Preferably, in the step (4), the separation conditions of the high performance liquid chromatography are as follows:
a chromatographic column: angioent Eclipse XDB-C18A column;
mobile phase: solution A: 0.05% trifluoroacetic acid-water solution; and B, liquid B: 0.05% trifluoroacetic acid in acetonitrile;
linear gradient elution is adopted, 0-20min, and 5% -20% of B is adopted; 20-25min, 20% -100% B;
the flow rate was 1.0mL/min, the column temperature was 30 ℃ and the detection wavelength was 220 nm.
The amino acid sequences of the cod skin oligopeptides prepared by the separation and purification process are Glu-Gly-Gly-Tyr-Thr-Arg, Tyr-Val-Arg and Phe-Tyr-Glu respectively through MALDI-TOF-MS/MS analysis and identification.
Activity tests show that the alpha-glucosidase inhibitory activity IC of the three compounds505.2mg/mL, 7.59mg/mL, 13.4mg/mL, respectively.
Therefore, all three cod skin oligopeptides can be applied to preparation of the alpha-glucosidase inhibitor. Preferably, the cod skin oligopeptide with the amino acid sequence of Glu-Gly-Gly-Tyr-Thr-Arg has better alpha-glucosidase inhibition effect.
The action mechanism of the alpha-glucosidase inhibitor is as follows: competitively inhibits various alpha-glucosidase in small intestine to reduce the speed of starch decomposition into glucose, thereby slowing the absorption of glucose in intestinal tract and reducing postprandial hyperglycemia. Type ii diabetes is characterized by postprandial hyperglycemia with glucose toxicity that can exacerbate insulin resistance and insulin secretion deficiencies, and when only about 50% of the islet beta cell function remains, an increase in fasting glucose occurs and impaired glucose tolerance occurs.
Based on the research, the three cod skin oligopeptides disclosed by the invention can be further used for preparing anti-type II diabetes drugs, and preferably, the cod skin oligopeptides with the amino acid sequences of Glu-Gly-Gly-Tyr-Thr-Arg have better blood sugar inhibition effect.
Compared with the prior art, the invention has the beneficial effects that:
the invention discloses three cod skin oligopeptides with novel amino acid sequence structures;
aiming at the characteristics that the cod skin collagen peptide prepared by an enzymatic hydrolysis method is small in molecular weight, concentrated in molecular weight of a mixture and small in dispersity, the cod skin collagen peptide is roughly divided in a manner that Sephadex G-25 and Sephadex G-50 are connected in series, and then is further separated by a high performance liquid chromatography technology to finally obtain three novel cod skin oligopeptides;
activity tests show that the three codfish skin oligopeptides have alpha-glucosidase inhibition activity, can assist in reducing blood sugar, and can be used for preparing anti-type II diabetes drugs.
Drawings
FIG. 1 is an elution curve of a separated fraction obtained by separation through a Sephadex column in example 1, with an elution volume (mL) on the abscissa and an absorbance at a wavelength of 220nm on the ordinate;
FIG. 2 is an elution curve of a separated fraction obtained by separation through a Sephadex column in comparative example 1, with the abscissa being the elution volume (mL) and the ordinate being the absorbance at a wavelength of 220 nm;
FIG. 3 is an elution curve of a separated fraction obtained by separation through a Sephadex column in comparative example 2, with the abscissa being the elution volume (mL) and the ordinate being the absorbance at a wavelength of 220 nm;
FIG. 4 is an elution curve of a separated fraction obtained by separation through a Sephadex column in comparative example 3, with an elution volume (mL) on the abscissa and an absorbance at a wavelength of 220nm on the ordinate;
FIG. 5 is an elution curve of a separated fraction obtained by separation through a Sephadex column in comparative example 4, with an elution volume (mL) on the abscissa and an absorbance at a wavelength of 220nm on the ordinate;
FIG. 6 is an elution curve of a separated fraction obtained by separation through a Sephadex column in comparative example 5, with an elution volume (mL) on the abscissa and an absorbance at a wavelength of 220nm on the ordinate;
FIG. 7 is an elution curve of a fraction separated by Sephadex column chromatography in example 2, with elution volume (mL) on the abscissa and absorbance at a wavelength of 220nm on the ordinate.
The specific implementation mode is as follows:
example 1
(1) 100g of Alaska pollack skin, 0.2g of pancreatin and 600mL of water are placed in a 1000mL beaker and placed in a thermostatic water bath at 55 ℃, the pH value is adjusted to be 6.0, a stirrer is started to stir reaction liquid, the rotating speed of the stirrer is controlled to be 300rpm, the reaction is carried out for 8 hours, the temperature is increased to 90 ℃, enzyme deactivation is carried out for 20 minutes, the reaction liquid is taken out, and filtration is carried out to obtain filtrate, namely the cod skin collagen peptide mixed peptide. The activity test shows that the inhibition activity IC50 of the cod skin collagen peptide mixed peptide on alpha-glucosidase is 50.4 mg/mL.
(2) Ultrafiltering the filtrate with hollow fiber polysulfone ultrafiltration membrane with molecular weight cutoff of 3000Da, collecting filtrate, concentrating, spray drying to obtain cod skin collagen peptide product with molecular weight less than 3000Da, weighing cod skin collagen peptide 2G, adding water 2mL for dissolving, loading 1mL collagen peptide water solution on Sephadex series chromatographic column, controlling column flow rate to 1.2mL/min, wherein the Sephadex series chromatographic column is formed by serially connecting 100 mesh Sephadex G-25 and 60 mesh Sephadex G-50, and eluting to obtain separated components A and B (the elution curve of two separated components is shown in figure 1).
Activity tests show that the separated components A and B have the inhibiting activity IC on alpha-glucosidase5018.2mg/mL and 25.3mg/mL, respectively.
(3) Separating the components by gel chromatography by using Re-HPLC technology respectively, wherein the separation conditions are as follows: a chromatographic column: angilent Eclipse XDB-C18 column (250X 4.6mm, 5 μm) mobile phase: solution A: 0.05% aqueous trifluoroacetic acid (TFA), liquid B: 0.05% TFA-acetonitrile solution, linear gradient elution, 0-20min, 5% -20% B; 20-25min, 20% -100% B, flow rate of 1.0mL/min, column temperature: 30 ℃, detection wavelength: 220 nm.
Through MALDI-TOF-MS/MS analysis, three cod skin oligopeptides are obtained by separation in the embodiment, and the amino acid sequences are Glu-Gly-Gly-Tyr-Thr-Arg, Tyr-Val-Arg and Phe-Tyr-Glu respectively.
Activity tests show that the alpha-glucosidase inhibitory activity IC of the three compounds505.2mg/mL, 7.59mg/mL, 13.4mg/mL, respectively.
Three cod skin oligopeptides Glu-Gly-Gly-Tyr-Thr-Arg, Tyr-Val-Arg and Phe-Tyr-Glu separated in the example were subjected to a blood glucose lowering animal test, and found that:
the three cod skin oligopeptides can inhibit the activity of alpha-amylase, reduce the absorption speed of sugar and obviously improve the sugar tolerance, the experimental results are shown in tables 1, 2 and 3, the table 1 shows the influence of Glu-Gly-Gly-Tyr-Thr-Arg on the starch load tolerance of a alloxan mouse, and the results show that the blood sugar value is obviously lower than that of a model control group (P <0.05) at the time point of 1h when starch is given to a 0.2g/kg dose group and at the time points of 0.5, 1, 2 and 3h after starch is given to a 0.5g/kg dose group. In addition, each dosage group can reduce the area under the curve and show obvious dosage relation.
TABLE 1 Effect of Glu-Gly-Gly-Tyr-Thr-Arg on starch load tolerance in alloxan diabetic mice: (
n＝10)
Note:△△P<0.05 (compared to model control group). times.P<0.05 (compared with normal control group)
Table 2 shows the influence of Tyr-Val-Arg on starch load tolerance of a tetraoxypyrimidinic diabetic model mouse, and the results in Table 2 show that blood glucose values at time points of 0.5, 1, 2 and 3h of starch given at a 1.0g/kg dose and 0.5, 1 and 2h of starch given at a 0.5g/kg dose are obviously lower than those of a model control group (P < 0.05). Compared with the model control group, the blood sugar value of each dose rises slowly, and the peak value is reduced; but also can reduce the area under the curve and show obvious dose relation.
TABLE 2 Effect of Tyr-Val-Arg on starch load tolerance in alloxan mice: (
n＝10)
Note:△△P<0.05 (compared to model control group). times.P<0.05 (compared with normal control group)
Table 3 shows the influence of Phe-Tyr-Glu on starch load tolerance of alloxan mice, and the results show that the blood sugar value is obviously lower than that of a model control group (P is less than 0.05) at the time point of 1h when starch is administered to a 0.2g/kg dose group and at the time points of 0.5 h, 1h, 2h and 3h after starch is administered to a 0.5g/kg dose group. In addition, each dosage group can reduce the area under the curve and show obvious dosage relation.
TABLE 3 influence of Phe-Tyr-Glu on starch load tolerance in alloxan diabetic mice: (
n＝10)
Note:△△P<0.05 (compared to model control group). times.P<0.05 (compared with normal control group)
Comparative example 1
(1) 100g of Alaska pollack skin, 0.2g of pancreatin and 600mL of water are placed in a 1000mL beaker and placed in a thermostatic water bath at 55 ℃, the pH value is adjusted to be 6.0, a stirrer is started to stir reaction liquid, the rotating speed of the stirrer is controlled to be 300rpm, the reaction is carried out for 8 hours, the temperature is increased to 90 ℃, enzyme deactivation is carried out for 20 minutes, the reaction liquid is taken out, and filtering is carried out, so that the pollack skin collagen peptide mixed peptide is obtained.
(2) Ultrafiltering the filtrate with hollow fiber polysulfone ultrafiltration membrane with molecular weight cutoff of 3000Da, collecting filtrate, concentrating, spray drying to obtain cod skin collagen peptide product with molecular weight less than 3000Da, weighing cod skin collagen peptide 2G, adding water 2mL for dissolving, loading 1mL collagen peptide water solution on Sephadex chromatographic column with flow rate of 1.2mL/min, and connecting Sephadex series chromatographic column as 100 mesh Sephadex G-25 Sephadex column.
Observation of the elution curve shows that the separation process cannot realize effective separation.
Comparative examples 2 to 4
The process flow of the step (1) and the step (2) is the same as that of the comparative example 1, except that 60-mesh Sephadex G-50 Sephadex columns, 100-mesh Sephadex G-10 Sephadex columns and 100-mesh Sephadex G-15 Sephadex columns are respectively used.
Observing elution curves of various proportions, finding that the separation process can not realize effective separation.
Comparative example 5
The process flow of the step (1) and the step (2) is the same as that of the comparative example 1, and the difference is only that a Sephadex tandem chromatographic column is adopted, and 60-mesh Sephadex resin Sephadex G-25 and 60-mesh Sephadex resin Sephadex G-50 are connected in series to form the Sephadex chromatographic column.
Observation of the elution curve shows that the separation process cannot realize effective separation.
Comparing fig. 1 with fig. 2-6, it can be found that effective separation of cod skin collagen peptide can be realized only by using a Sephadex chromatographic column formed by connecting 100-mesh Sephadex G-25 and 60-mesh Sephadex G-50 in series, so that possibility is provided for further separation of three cod skin oligopeptides.
Example 2
(1) 200g of Alaska pollack skin, 0.4g of pancreatin and 1200mL of water are placed in a 2000mL beaker and placed in a thermostatic water bath at 55 ℃, the pH value is adjusted to be 6.0, a stirrer is started to stir reaction liquid, the rotating speed of the stirrer is controlled to be 300rpm, the reaction is carried out for 8 hours, the temperature is increased to 90 ℃, enzyme deactivation is carried out for 20 minutes, the reaction liquid is taken out, filtration is carried out, and the obtained pollack skin collagen peptide mixed peptide has alpha-glucosidase inhibition activity IC50It was 52.7 mg/mL.
(2) And (3) performing ultrafiltration on the filtrate by using a hollow fiber polysulfone ultrafiltration membrane with the molecular weight cutoff of 3000Da, taking the filtrate, concentrating the filtrate, and performing spray drying to obtain a finished product of the cod skin collagen peptide with the molecular weight of less than 3000 Da. Weighing 2G of cod skin collagen peptide, adding 2mL of water for dissolving, putting 1mL of collagen peptide aqueous solution on a gel tandem column, wherein the Sephadex tandem column is formed by connecting 100-mesh Sephadex G-25 and 60-mesh Sephadex G-50 in series, controlling the flow rate of the column to be 0.7mL/min, and collecting a separation component A, B (an elution curve is shown in figure 7).
(3) Separating the components by gel chromatography by using Re-HPLC technology respectively, wherein the separation conditions are as follows: a chromatographic column: angilent Eclipse XDB-C18 column (250X 4.6mm, 5 μm) mobile phase: solution A: 0.05% aqueous trifluoroacetic acid (TFA), liquid B: 0.05% TFA-acetonitrile solution, linear gradient elution, 0-20min, 5% -20% B; 20-25min, 20% -100% B, flow rate of 1.0mL/min, column temperature: 30 ℃, detection wavelength: 220 nm. Separating to obtain three cod skin oligopeptides, wherein the amino acid sequences are Glu-Gly-Gly-Tyr-Thr-Arg, Tyr-Val-Arg and Phe-Tyr-Glu respectively.
Example 3
(1) Placing 1000g of Alaska pollack skin, 2g of pancreatin and 6000mL of water in a self-made stainless steel container, placing the container in a constant-temperature water bath at 55 ℃, adjusting the pH value to 6.0, starting a stirrer to stir reaction liquid, controlling the rotating speed of the stirrer to be 300rpm, reacting for 8 hours, heating to 90 ℃, inactivating enzyme for 20 minutes, taking out the reaction liquid, filtering, and obtaining the Alaska Pollack collagen peptide mixed peptide with alpha-glucosidase inhibition activity IC50It was 51.9 mg/mL.
(2) And (3) performing ultrafiltration on the filtrate by using a hollow fiber polysulfone ultrafiltration membrane with the molecular weight cutoff of 3000Da, taking the filtrate, concentrating the filtrate, and performing spray drying to obtain a finished product of the cod skin collagen peptide with the molecular weight of less than 3000 Da. And spray drying the filtrate to obtain the finished product of the cod skin collagen peptide. Weighing 2G of cod skin collagen peptide, adding 2mL of water for dissolving, feeding 1mL of collagen peptide aqueous solution to a gel tandem column, wherein the Sephadex tandem column is formed by connecting 100-mesh Sephadex G-25 and 60-mesh Sephadex G-50 in series, controlling the flow rate of the column to be 1.0mL/min, and collecting a separation component A, B.
(3) Separating the components by gel chromatography by using Re-HPLC technology respectively, wherein the separation conditions are as follows: a chromatographic column: angilent Eclipse XDB-C18 column (250X 4.6mm, 5 μm) mobile phase: solution A: 0.05% aqueous trifluoroacetic acid (TFA), liquid B: 0.05% TFA-acetonitrile solution, linear gradient elution, 0-20min, 5% -20% B; 20-25min, 20% -100% B, flow rate of 1.0mL/min, column temperature: 30 ℃, detection wavelength: 220 nm. Separating to obtain three cod skin oligopeptides, wherein the amino acid sequences are Glu-Gly-Gly-Tyr-Thr-Arg, Tyr-Val-Arg and Phe-Tyr-Glu respectively.
Example 4
(1) 2kg of Alaska pollack skin, 4g of pancreatin and 12kg of water are placed in a self-made stainless steel container, the reaction temperature is controlled to be 55 ℃, the pH value is adjusted to be 6.0, a stirrer is started to stir reaction liquid, the rotating speed of the stirrer is controlled to be 300rpm, the reaction is carried out for 8 hours, the temperature is increased to 90 ℃, enzyme deactivation is carried out for 20 minutes, the reaction liquid is taken out, filtration is carried out, and the obtained pollack skin collagen peptide mixed peptide has alpha-glucosidase inhibition activity IC50It was 48.8 mg/mL.
(2) And (3) performing ultrafiltration on the filtrate by using a hollow fiber polysulfone ultrafiltration membrane with the molecular weight cutoff of 3000Da, taking the filtrate, concentrating the filtrate, and performing spray drying to obtain a finished product of the cod skin collagen peptide with the molecular weight of less than 3000 Da. And spray drying the filtrate to obtain the finished product of the cod skin collagen peptide. Weighing 2G of cod skin collagen peptide, adding 2mL of water for dissolving, feeding 1mL of collagen peptide aqueous solution to a gel tandem column, wherein the Sephadex tandem column is formed by connecting 100-mesh Sephadex G-25 and 60-mesh Sephadex G-50 in series, controlling the flow rate of the column to be 1.0mL/min, and collecting a separation component A, B.
(3) Separating the components by gel chromatography by using Re-HPLC technology respectively, wherein the separation conditions are as follows: a chromatographic column: angilent Eclipse XDB-C18 column (250X 4.6mm, 5 μm) mobile phase: solution A: 0.05% aqueous trifluoroacetic acid (TFA), liquid B: 0.05% TFA-acetonitrile solution, linear gradient elution, 0-20min, 5% -20% B; 20-25min, 20% -100% B, flow rate of 1.0mL/min, column temperature: 30 ℃, detection wavelength: 220 nm. Separating to obtain three cod skin oligopeptides, wherein the amino acid sequences are Glu-Gly-Gly-Tyr-Thr-Arg, Tyr-Val-Arg and Phe-Tyr-Glu respectively.
Example 5
(1) 50kg of Alaska pollack skin, 100g of pancreatin and 300kg of water are placed in an enzymolysis reaction kettle, the reaction temperature is set to 55 ℃, the pH value is adjusted to 6.0, a stirrer is started to stir reaction liquid, the rotating speed of the stirrer is controlled to be 300rpm, the reaction is carried out for 8h, the temperature is increased to 90 ℃, enzyme deactivation is carried out for 20min, the reaction liquid is taken out and filtered, and the obtained pollack skin collagen peptide mixed peptide has alpha-glucosidase inhibition activity IC5053.8 mg/mL.
(2) And (3) performing ultrafiltration on the filtrate by using a hollow fiber polysulfone ultrafiltration membrane with the molecular weight cutoff of 3000Da, taking the filtrate, concentrating the filtrate, and performing spray drying to obtain a finished product of the cod skin collagen peptide with the molecular weight of less than 3000 Da. And spray drying the filtrate to obtain the finished product of the cod skin collagen peptide. Weighing 2G of cod skin collagen peptide, adding 2mL of water for dissolving, feeding 1mL of collagen peptide aqueous solution to a gel tandem column, wherein the Sephadex tandem column is formed by connecting 100-mesh Sephadex G-25 and 60-mesh Sephadex G-50 in series, controlling the flow rate of the column to be 1.2mL/min, and collecting a separation component A, B.
(3) Separating the components by gel chromatography by using Re-HPLC technology respectively, wherein the separation conditions are as follows: a chromatographic column: angilent Eclipse XDB-C18 column (250X 4.6mm, 5 μm) mobile phase: solution A: 0.05% aqueous trifluoroacetic acid (TFA), liquid B: 0.05% TFA-acetonitrile solution, linear gradient elution, 0-20min, 5% -20% B; 20-25min, 20% -100% B, flow rate of 1.0mL/min, column temperature: 30 ℃, detection wavelength: 220 nm. Separating to obtain three cod skin oligopeptides, wherein the amino acid sequences are Glu-Gly-Gly-Tyr-Thr-Arg, Tyr-Val-Arg and Phe-Tyr-Glu respectively.
Claims (2)
1. The application of the codfish skin oligopeptide in preparation of the alpha-glucosidase inhibitor is characterized in that the amino acid sequence of the codfish skin oligopeptide is Phe-Tyr-Glu.
2. The application of the cod skin oligopeptide in preparing the anti-type II diabetes medicine is characterized in that the amino acid sequence of the cod skin oligopeptide is Phe-Tyr-Glu.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010455884.5A CN111574585B (en) | 2019-01-30 | 2019-01-30 | Cod skin oligopeptide and separation and purification method and application thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010455884.5A CN111574585B (en) | 2019-01-30 | 2019-01-30 | Cod skin oligopeptide and separation and purification method and application thereof |
| CN201910091803.5A CN109776652B (en) | 2019-01-30 | 2019-01-30 | Codfish skin oligopeptide, separation and purification method thereof, and application of codfish skin oligopeptide in preparation of alpha-glucosidase inhibitor and anti-type II diabetes drug |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910091803.5A Division CN109776652B (en) | 2019-01-30 | 2019-01-30 | Codfish skin oligopeptide, separation and purification method thereof, and application of codfish skin oligopeptide in preparation of alpha-glucosidase inhibitor and anti-type II diabetes drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111574585A CN111574585A (en) | 2020-08-25 |
| CN111574585B true CN111574585B (en) | 2021-10-01 |
Family
ID=66503847
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010455884.5A Active CN111574585B (en) | 2019-01-30 | 2019-01-30 | Cod skin oligopeptide and separation and purification method and application thereof |
| CN201910091803.5A Active CN109776652B (en) | 2019-01-30 | 2019-01-30 | Codfish skin oligopeptide, separation and purification method thereof, and application of codfish skin oligopeptide in preparation of alpha-glucosidase inhibitor and anti-type II diabetes drug |
| CN202010454774.7A Active CN111606972B (en) | 2019-01-30 | 2019-01-30 | Codfish skin oligopeptide, separation and purification thereof, and application of codfish skin oligopeptide in preparation of alpha-glucosidase inhibitor and anti-type II diabetes drug |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910091803.5A Active CN109776652B (en) | 2019-01-30 | 2019-01-30 | Codfish skin oligopeptide, separation and purification method thereof, and application of codfish skin oligopeptide in preparation of alpha-glucosidase inhibitor and anti-type II diabetes drug |
| CN202010454774.7A Active CN111606972B (en) | 2019-01-30 | 2019-01-30 | Codfish skin oligopeptide, separation and purification thereof, and application of codfish skin oligopeptide in preparation of alpha-glucosidase inhibitor and anti-type II diabetes drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN111574585B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112661809B (en) * | 2021-01-18 | 2022-12-27 | 杭州迦微生物科技有限公司 | Method for extracting blood-enriching peptide from fish skin and product thereof |
| CN113005166B (en) * | 2021-04-14 | 2022-08-16 | 中国海洋大学 | Cod polypeptide with xanthine oxidase inhibitory activity |
| CN113337565B (en) * | 2021-06-22 | 2023-03-17 | 中国科学院南海海洋研究所 | Marine biological active peptide with obvious skin sunburn protection effect and preparation method and application thereof |
| CN114751958A (en) * | 2022-05-17 | 2022-07-15 | 哈尔滨腾凝科技有限公司 | Method for extracting polypeptide inhibiting DPP-4 activity from salmon skin |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102741269A (en) * | 2009-10-22 | 2012-10-17 | 帝国创新有限公司 | Gadd45beta targeting agents |
| WO2014016787A2 (en) * | 2012-07-24 | 2014-01-30 | Pharma Bio Llc | Peptide-based compounds and uses thereof to treat beta-amyloid accumulation |
| CN103952455A (en) * | 2014-04-14 | 2014-07-30 | 华南理工大学 | Method for preparing Fringed iris rhizome antidiabetic polypeptides |
| WO2016033774A1 (en) * | 2014-09-04 | 2016-03-10 | 天津医科大学 | Β-lamella blocking peptide used for preventing and/or treating alzheimer's disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4563305A (en) * | 1981-01-07 | 1986-01-07 | University Of Miami | Radiolabelled substrates for assaying mammalian enzymes |
| ES2319475B1 (en) * | 2005-06-08 | 2010-02-16 | Consejo Superior Investig. Cientificas | BIOACTIVE PEPTIDES IDENTIFIED IN ENZYMATIC HYDROLYZES OF LACTEE CASEINS AND PROCEDURE OF OBTAINING. |
| PL2254906T3 (en) * | 2008-03-18 | 2017-04-28 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| CN104372054A (en) * | 2014-10-14 | 2015-02-25 | 中国海洋大学 | Codfish skin collagen-derived chelating peptide and preparation method thereof |
| CN110105428B (en) * | 2015-06-23 | 2022-08-05 | 首都医科大学 | Leu-Arg-Ala-Pro-Leu-Tyr-Val heptapeptide, synthesis, activity and application thereof |
| CN105906709A (en) * | 2016-05-17 | 2016-08-31 | 青岛海博瑞克生物科技有限公司 | Alaska Pollock fish skin active oligopeptides as well as synthesis method and application thereof |
| CN107164445B (en) * | 2017-06-08 | 2020-01-10 | 中国农业大学 | Fish skin protein peptide with DPP-IV inhibition function and preparation method and application thereof |
| CN109182435B (en) * | 2018-10-23 | 2021-12-17 | 浙江海洋大学 | Preparation method of biological source dipeptidyl peptidase-IV inhibitor |
-
2019
- 2019-01-30 CN CN202010455884.5A patent/CN111574585B/en active Active
- 2019-01-30 CN CN201910091803.5A patent/CN109776652B/en active Active
- 2019-01-30 CN CN202010454774.7A patent/CN111606972B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102741269A (en) * | 2009-10-22 | 2012-10-17 | 帝国创新有限公司 | Gadd45beta targeting agents |
| WO2014016787A2 (en) * | 2012-07-24 | 2014-01-30 | Pharma Bio Llc | Peptide-based compounds and uses thereof to treat beta-amyloid accumulation |
| CN103952455A (en) * | 2014-04-14 | 2014-07-30 | 华南理工大学 | Method for preparing Fringed iris rhizome antidiabetic polypeptides |
| WO2016033774A1 (en) * | 2014-09-04 | 2016-03-10 | 天津医科大学 | Β-lamella blocking peptide used for preventing and/or treating alzheimer's disease |
Non-Patent Citations (1)
| Title |
|---|
| Purification and properties of an aminopeptidase from the mid-gut gland of scallop (Patinopecten yessoensis);Umetsu H等;《Comparative Biochemistry And Physiology B-biochemistry & Molecular Biology》;20031231;第136卷(第4期);第940页左栏第3段、图4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109776652B (en) | 2020-08-18 |
| CN109776652A (en) | 2019-05-21 |
| CN111606972B (en) | 2022-04-05 |
| CN111606972A (en) | 2020-09-01 |
| CN111574585A (en) | 2020-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111574585B (en) | Cod skin oligopeptide and separation and purification method and application thereof | |
| CN101284017B (en) | A method for continuously preparing birds nest extract with narrow molecular weight distribution by enzymolysis and membrane filtration coupling technique | |
| CN110772630A (en) | Compound bitter gourd peptide oral liquid for activating insulin receptor and regulating blood sugar and preparation method thereof | |
| GB2607449A (en) | Activated insulin, compound Momordica charantia peptide oral medicine for treatment of diabetes, and preparation method | |
| CN114751958A (en) | Method for extracting polypeptide inhibiting DPP-4 activity from salmon skin | |
| JP4772884B2 (en) | Pharmaceutical composition for suppressing an increase in blood glucose level and use of a polypeptide for producing a drug for suppressing an increase in blood glucose level | |
| CN108409805B (en) | Separation and purification method of delphinidin-3-O-galactoside and application thereof | |
| CN111088310A (en) | Soybean peptide with α -glucosidase activity inhibition function, and preparation method and application thereof | |
| CN110643662A (en) | Fishy smell-free bitter fish protein peptide and preparation method thereof | |
| KR101219146B1 (en) | Protein hydrolysate with antidiabetic effect | |
| CN108864224B (en) | Separation and purification method of malvidin-3-O-arabinoside and application thereof | |
| CN113845567B (en) | Tuna roe dipeptidyl peptidase IV inhibition oligopeptide | |
| CN108822168B (en) | Separation and purification method of malvidin-3-O-galactoside and application thereof | |
| CN114306419A (en) | Method for extracting alpha-amylase inhibitor from white kidney beans | |
| CN100390199C (en) | Method for extracting insulin type growth factor-1 from fresh pilose antler | |
| CN108686200B (en) | For treating the polypeptide and combinations thereof of metabolic system disease | |
| CN109810094A (en) | A kind of preparation method of Egelieting | |
| CN111549085B (en) | Method for preparing dipeptidyl peptidase IV inhibitory active peptide by using walnut meal and application thereof | |
| WO2011068150A1 (en) | Glucagon-like peptide-1 secretion enhancer | |
| CN114990180B (en) | Wheat peptide with auxiliary blood sugar reducing effect and preparation method and application thereof | |
| CN116444606A (en) | Donkey skin oligopeptide and application thereof | |
| CN116444617A (en) | Donkey skin oligopeptide and application thereof | |
| CN107217084A (en) | A kind of processing method of functional protein peptide product | |
| CN116606350B (en) | Sea cucumber peptide and production method and application thereof | |
| CN107177653B (en) | Method for preparing blood sugar reducing peptide by utilizing needle mushroom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |